Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Lupin updates on shipment of Mirabegron ER Tablets
Piramal Pharma has reported total income of Rs. 2,578.74 crores during the period ended March 31, 2024
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
